These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30585257)

  • 1. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F
    Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617
    [No Abstract]   [Full Text] [Related]  

  • 7. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
    J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
    Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
    Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
    Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
    Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY
    J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
    Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
    Manfredi S; Bouché O; Rougier P; Dahan L; Loriot MA; Aparicio T; Etienne PL; Lafargue JP; Lécaille C; Legoux JL; Le Malicot K; Maillard E; Lecomte T; Khemissa F; Breysacher G; Michel P; Mitry E; Bedenne L
    Mol Cancer Ther; 2015 Dec; 14(12):2782-8. PubMed ID: 26494856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
    Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
    Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
    Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.